Kelly Olino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kelly Olino has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Daniel Jacobs
Department of Surgery, Yale School of Medicine, New Haven, CT 06511, USA
4 shared publicationsJames Clune
Department of Surgery, Yale School of Medicine, New Haven, CT 06511, USA
4 shared publicationsStephan Ariyan
Department of Surgery, Yale University School of Medicine, New Haven, CT, United States
4 shared publicationsHarriet Kluger
Division of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, USA
3 shared publicationsAlexander Frey
Department of Surgery, Yale School of Medicine, New Haven, CT 06511, USA
2 shared publicationsAndrew Esposito
Division of Surgical Oncology, Department of Surgery, Yale School of Medicine, New Haven, USA
2 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (10) , 116359
Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma
- 1 October 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (10) , 116359
Open AccessTargeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma
- 27 January 2025
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 34 (3) , 453-471
Non-Cutaneous Melanoma
- 27 January 2025
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 34 (3) , 453-471
Non-Cutaneous Melanoma
- 23 January 2025
- Published by Elsevier in Surgical Clinics of North America
- Vol. 105 (3) , 639-649
Updates in Management of Local-Regionally Advanced Merkel Cell Carcinoma
- 23 January 2025
- Published by Elsevier in Surgical Clinics of North America
- Vol. 105 (3) , 639-649
Updates in Management of Local-Regionally Advanced Merkel Cell Carcinoma
- Open Access
- 6 February 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1336441
Immunotherapy utilization in stage IIIA melanoma: less may be more
Background: Immunotherapy agents are approved for adjuvant treatment of stage III melanoma; however, evidence for survival benefit in early stage III disease is lacking. Current guidelines for adjuvant immunotherapy utilization in stage IIIA rely on clinician judgment, creating an opportunity for significant variation in prescribing patterns. This study aimed to characterize current immunotherapy practice variations and to compare patient outcomes for different prescribing practices in stage IIIA melanoma.Study design: Patients with melanoma diagnosed from 2015-2019 that met American Joint Committee on Cancer 8th edition criteria for stage IIIA and underwent resection were identified in the National Cancer Database. Multiple imputation by chained equations replaced missing values. Factors associated with receipt of adjuvant immunotherapy were identified. Multivariable Cox proportional hazards regression compared overall survival across groups.Results: Of 4,432 patients included in the study, 34% received adjuvant immunotherapy. Patients had lower risk-adjusted odds of receiving immunotherapy if they were treated at an academic center (OR=0.48, 95%CI=0.33-0.72, p<0.001 vs. community facility) or at a high-volume center (OR=0.69, 0.56-0.84, p<0.001 vs. low-volume). Immunotherapy receipt was not associated with risk-adjusted survival (p=0.095). Moreover, patients treated at high-volume centers experienced longer overall risk-adjusted survival than those treated at low-volume centers (HR=0.52, 0.29-0.93, p=0.030). Risk-adjusted survival trended toward being longer at academic centers than at community centers, but the difference was not statistically significant.Conclusion: Academic and high-volume centers utilize significantly less adjuvant immunotherapy in stage IIIA melanoma than community and low-volume centers without compromise in overall survival. These findings suggest that this population may benefit from more judicious immunotherapy utilization.
- 6 February 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1336441
Open AccessImmunotherapy utilization in stage IIIA melanoma: less may be more
Background: Immunotherapy agents are approved for adjuvant treatment of stage III melanoma; however, evidence for survival benefit in early stage III disease is lacking. Current guidelines for adjuvant immunotherapy utilization in stage IIIA rely on clinician judgment, creating an opportunity for significant variation in prescribing patterns. This study aimed to characterize current immunotherapy practice variations and to compare patient outcomes for different prescribing practices in stage IIIA melanoma.Study design: Patients with melanoma diagnosed from 2015-2019 that met American Joint Committee on Cancer 8th edition criteria for stage IIIA and underwent resection were identified in the National Cancer Database. Multiple imputation by chained equations replaced missing values. Factors associated with receipt of adjuvant immunotherapy were identified. Multivariable Cox proportional hazards regression compared overall survival across groups.Results: Of 4,432 patients included in the study, 34% received adjuvant immunotherapy. Patients had lower risk-adjusted odds of receiving immunotherapy if they were treated at an academic center (OR=0.48, 95%CI=0.33-0.72, p<0.001 vs. community facility) or at a high-volume center (OR=0.69, 0.56-0.84, p<0.001 vs. low-volume). Immunotherapy receipt was not associated with risk-adjusted survival (p=0.095). Moreover, patients treated at high-volume centers experienced longer overall risk-adjusted survival than those treated at low-volume centers (HR=0.52, 0.29-0.93, p=0.030). Risk-adjusted survival trended toward being longer at academic centers than at community centers, but the difference was not statistically significant.Conclusion: Academic and high-volume centers utilize significantly less adjuvant immunotherapy in stage IIIA melanoma than community and low-volume centers without compromise in overall survival. These findings suggest that this population may benefit from more judicious immunotherapy utilization.
- 21 November 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (3) , 1865-1879
Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma
In the last decade, immunotherapy has become the cornerstone in the management of patients with melanoma, the foremost cause of skin-cancer-related death i
- 21 November 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (3) , 1865-1879
Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma
In the last decade, immunotherapy has become the cornerstone in the management of patients with melanoma, the foremost cause of skin-cancer-related death i
- Open Access
- 8 May 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
The role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative disease
Background: Previous studies demonstrate minimal utility of pre-operative imaging for low-risk melanoma; however, imaging may be more critical for patients with high-risk disease. Our study evaluates the impact of peri-operative cross-sectional imaging in patients with T3b-T4b melanoma.Methods: Patients with T3b-T4b melanoma who underwent wide local excision were identified from a single institution (1/1/2005 – 12/31/2020). Cross-sectional imaging was defined as body CT, PET and/or MRI in the perioperative period, with the following findings: in-transit or nodal disease, metastatic disease, incidental cancer, or other. Propensity scores were created for the odds of undergoing pre-operative imaging. Recurrence free survival was analyzed using the Kaplan-Meier method and log-rank test.Results: A total of 209 patients were identified with a median age of 65 (IQR 54-76), of which the majority were male (65.1%), with nodular melanoma (39.7%) and T4b disease (47.9%). Overall, 55.0% underwent pre-operative imaging. There were no differences in imaging findings between the pre- and post-operative cohorts. After propensity-score matching, there was no difference in recurrence free survival. Sentinel node biopsy was performed in 77.5% patients, with 47.5% resulting in a positive result.Conclusion: Pre-operative cross-sectional imaging does not impact the management of patients with high-risk melanoma. Careful consideration of imaging use is critical in the management of these patients and highlights the importance of sentinel node biopsy for stratification and decision making.
- 8 May 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Open AccessThe role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative disease
Background: Previous studies demonstrate minimal utility of pre-operative imaging for low-risk melanoma; however, imaging may be more critical for patients with high-risk disease. Our study evaluates the impact of peri-operative cross-sectional imaging in patients with T3b-T4b melanoma.Methods: Patients with T3b-T4b melanoma who underwent wide local excision were identified from a single institution (1/1/2005 – 12/31/2020). Cross-sectional imaging was defined as body CT, PET and/or MRI in the perioperative period, with the following findings: in-transit or nodal disease, metastatic disease, incidental cancer, or other. Propensity scores were created for the odds of undergoing pre-operative imaging. Recurrence free survival was analyzed using the Kaplan-Meier method and log-rank test.Results: A total of 209 patients were identified with a median age of 65 (IQR 54-76), of which the majority were male (65.1%), with nodular melanoma (39.7%) and T4b disease (47.9%). Overall, 55.0% underwent pre-operative imaging. There were no differences in imaging findings between the pre- and post-operative cohorts. After propensity-score matching, there was no difference in recurrence free survival. Sentinel node biopsy was performed in 77.5% patients, with 47.5% resulting in a positive result.Conclusion: Pre-operative cross-sectional imaging does not impact the management of patients with high-risk melanoma. Careful consideration of imaging use is critical in the management of these patients and highlights the importance of sentinel node biopsy for stratification and decision making.
- Open Access
- 10 April 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (7)
Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
Targeting tumor-associated blood vessels to increase immune infiltration may enhance treatment effectiveness, yet limited data exist regarding anti-angiogenesis effects on the tumor microenvironment (TME). We hypothesized that dual targeting of angiogenesis with immune checkpoints would improve both intracranial and extracranial disease. We used subcutaneous and left ventricle melanoma models to evaluate anti–PD-1/anti-VEGF and anti–PD-1/lenvatinib (pan-VEGFR inhibitor) combinations. Cytokine/chemokine profiling and flow cytometry were performed to assess signaling and immune-infiltrating populations. An in vitro blood-brain barrier (BBB) model was utilized to study intracranial treatment effects on endothelial integrity and leukocyte transmigration. Anti–PD-1 with either anti-VEGF or lenvatinib improved survival and decreased tumor growth in systemic melanoma murine models; treatment increased Th1 cytokine/chemokine signaling. Lenvatinib decreased tumor-associated macrophages but increased plasmacytoid DCs early in treatment; this effect was not evident with anti-VEGF. Both lenvatinib and anti-VEGF resulted in decreased intratumoral blood vessels. Although anti-VEGF promoted endothelial stabilization in an in vitro BBB model, while lenvatinib did not, both regimens enabled leukocyte transmigration. The combined targeting of PD-1 and VEGF or its receptors promotes enhanced melanoma antitumor activity, yet their effects on the TME are quite different. These studies provide insights into dual anti–PD-1 and anti-angiogenesis combinations.
- 10 April 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (7)
Open AccessLenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
Targeting tumor-associated blood vessels to increase immune infiltration may enhance treatment effectiveness, yet limited data exist regarding anti-angiogenesis effects on the tumor microenvironment (TME). We hypothesized that dual targeting of angiogenesis with immune checkpoints would improve both intracranial and extracranial disease. We used subcutaneous and left ventricle melanoma models to evaluate anti–PD-1/anti-VEGF and anti–PD-1/lenvatinib (pan-VEGFR inhibitor) combinations. Cytokine/chemokine profiling and flow cytometry were performed to assess signaling and immune-infiltrating populations. An in vitro blood-brain barrier (BBB) model was utilized to study intracranial treatment effects on endothelial integrity and leukocyte transmigration. Anti–PD-1 with either anti-VEGF or lenvatinib improved survival and decreased tumor growth in systemic melanoma murine models; treatment increased Th1 cytokine/chemokine signaling. Lenvatinib decreased tumor-associated macrophages but increased plasmacytoid DCs early in treatment; this effect was not evident with anti-VEGF. Both lenvatinib and anti-VEGF resulted in decreased intratumoral blood vessels. Although anti-VEGF promoted endothelial stabilization in an in vitro BBB model, while lenvatinib did not, both regimens enabled leukocyte transmigration. The combined targeting of PD-1 and VEGF or its receptors promotes enhanced melanoma antitumor activity, yet their effects on the TME are quite different. These studies provide insights into dual anti–PD-1 and anti-angiogenesis combinations.
- 26 September 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (S3) , 736-737
ASO Visual Abstract: Merkel Cell Carcinoma—Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally
- 26 September 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (S3) , 736-737
ASO Visual Abstract: Merkel Cell Carcinoma—Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally
- 14 September 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (1) , 1-2
ASO Author Reflections: The Utility of Overall Survival as an Outcome in the Study of Merkel Cell Carcinoma
- 14 September 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (1) , 1-2
ASO Author Reflections: The Utility of Overall Survival as an Outcome in the Study of Merkel Cell Carcinoma
- Open Access
- 7 September 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (1) , 415-424
Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally
Background: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. Our report describes the evolution of management and characteristics associated with recurrence, disease-specific survival (DSS) and overall survival (OS) in the treatment of MCC. Methods: A single institution retrospective review of MCC and SEER data to determine factors associated with RFS, DSS, and OS using a multivariable Cox regression on inverse-probability weighted cohorts. Results: One hundred fifty-nine patients were identified with a median age of 75. Of these, 96% were Caucasian and 60% male. Fifty-eight out of 159 (36%) of all patients were deceased with 21/58 (36%) dead from MCC with a median follow-up of 3.1 years. Institutionally, trends over time demonstrated an increased use of immunotherapy with a concomitant decrease in chemotherapy and decreased use of radiotherapy alone. Institutionally and nationally, there has been increased surgical nodal staging. Institutionally, factors associated with shorter DSS included advanced age, active cigarette smoker (p = 0.002), cT2 disease (p = 0.007), and MCC with unknown primary (p < 0.001). Institutionally, factors associated with shorter OS included ages ≥ 75 years (p < 0.001), an immunocompromised state (p < 0.001), truncal primary site (p = 0.002), and cT2 disease (HR 9.59, p < 0.001). Conclusion: Changing practice patterns in MCC management have been driven by the adoption of immunotherapy. Our study highlights that competing risks of mortality in MCC patients likely prevents OS from being an accurate surrogate outcome measure to understand factors associated with DSS.
- 7 September 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (1) , 415-424
Open AccessMerkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally
Background: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. Our report describes the evolution of management and characteristics associated with recurrence, disease-specific survival (DSS) and overall survival (OS) in the treatment of MCC. Methods: A single institution retrospective review of MCC and SEER data to determine factors associated with RFS, DSS, and OS using a multivariable Cox regression on inverse-probability weighted cohorts. Results: One hundred fifty-nine patients were identified with a median age of 75. Of these, 96% were Caucasian and 60% male. Fifty-eight out of 159 (36%) of all patients were deceased with 21/58 (36%) dead from MCC with a median follow-up of 3.1 years. Institutionally, trends over time demonstrated an increased use of immunotherapy with a concomitant decrease in chemotherapy and decreased use of radiotherapy alone. Institutionally and nationally, there has been increased surgical nodal staging. Institutionally, factors associated with shorter DSS included advanced age, active cigarette smoker (p = 0.002), cT2 disease (p = 0.007), and MCC with unknown primary (p < 0.001). Institutionally, factors associated with shorter OS included ages ≥ 75 years (p < 0.001), an immunocompromised state (p < 0.001), truncal primary site (p = 0.002), and cT2 disease (HR 9.59, p < 0.001). Conclusion: Changing practice patterns in MCC management have been driven by the adoption of immunotherapy. Our study highlights that competing risks of mortality in MCC patients likely prevents OS from being an accurate surrogate outcome measure to understand factors associated with DSS.